RxDoctor Payments Data

John Harvey

Family · McComb, MSNPI 1982012548

Payments from drug & device makers

$261in general payments, 2019–2025

Across 10 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Itamar Medical Inc$102
  • Lilly USA, LLC$44
  • Novo Nordisk$33
  • Exact Sciences$19
  • Xeris Pharmaceuticals, Inc.$19
  • Shield Therapeutics Inc$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$261 in reported general payments places this provider in the 40th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$127,019
Medicare patients
497
Services billed
3,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$76,978
JardianceEmpagliflozin81$65,384
OzempicSemaglutide46$41,384
XareltoRivaroxaban50$30,369
MounjaroTirzepatide24$22,613
JanuviaSitagliptin Phosphate16$20,023
EntrestoSacubitril/Valsartan25$17,544
JanumetSitagliptin Phos/Metformin Hcl13$13,230
Janumet XrSitagliptin Phos/Metformin Hcl14$9,868
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$8,194
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,352
FarxigaDapagliflozin Propanediol11$6,974
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,131
BenicarOlmesartan Medoxomil12$5,021
Breo ElliptaFluticasone/Vilanterol12$4,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$41,38446 claims
Lilly USA, LLCMounjaro$44$22,61324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,007 family providers in Mississippi.

Other family in McComb

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →